請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71985
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 邱浩傑(Hao-Chieh Chiu) | |
dc.contributor.author | Chia-I Chiu | en |
dc.contributor.author | 邱嘉儀 | zh_TW |
dc.date.accessioned | 2021-06-17T06:17:50Z | - |
dc.date.available | 2023-08-30 | |
dc.date.copyright | 2018-08-30 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-20 | |
dc.identifier.citation | 1. Leon-Sicairos, N., et al., Strategies of Intracellular Pathogens for Obtaining Iron from the Environment. Biomed Res Int, 2015. 2015: p. 476534.
2. Khan, N., et al., Manipulation of Costimulatory Molecules by Intracellular Pathogens: veni, vidi, vici!! PLoS Pathog, 2012. 8(6): p. e1002676. 3. Beare, P.A., et al., Advances in Genetic Manipulation of Obligate Intracellular Bacterial Pathogens. Frontiers in Microbiology, 2011. 2: p. 97. 4. Hybiske, K. and R.S. Stephens, Exit Strategies of Intracellular Pathogens. Nature Reviews Microbiology, 2008. 6: p. 99. 5. Fredlund, J. and J. Enninga, Cytoplasmic Access by Intracellular Bacterial Pathogens. Trends in Microbiology, 2014. 22(3): p. 128-137. 6. Khasnobis, S., V.E. Escuyer, and D. Chatterjee, Emerging Therapeutic Targets in Tuberculosis: Post-Genomic Era. Expert Opin Ther Targets, 2002. 6(1): p. 21-40. 7. Lawn, S.D. and A.I. Zumla, Tuberculosis. The Lancet, 2011. 378(9785): p. 57-72. 8. Coburn, B., G.A. Grassl, and B.B. Finlay, Salmonella, the Host and Disease: a Brief Review. Immunol Cell Biol, 2007. 85(2): p. 112-8. 9. Niki, Y. and T. Kishimoto, Epidemiology of Intracellular Pathogens. Clinical Microbiology and Infection, 1996. 1: p. S11-S13. 10. Maurin, M. and D. Raoult, Use of Aminoglycosides in Treatment of Infections Due to Intracellular bacteria. Antimicrob Agents Chemother, 2001. 45(11): p. 2977-86. 11. Grant, S.S. and D.T. Hung, Persistent Bacterial Infections, Antibiotic Tolerance, and the Oxidative Stress Response. Virulence, 2013. 4(4): p. 273-283. 12. Monack, D.M., A. Mueller, and S. Falkow, Persistent Bacterial Infections: the Interface of the Pathogen and the Host Immune System. Nature Reviews Microbiology, 2004. 2: p. 747. 13. Thi, E.P., U. Lambertz, and N.E. Reiner, Sleeping with the Enemy: How Intracellular Pathogens Cope with a Macrophage Lifestyle. PLoS Pathogens, 2012. 8(3): p. e1002551. 14. Ray, K., et al., Life on the Inside: the Intracellular Lifestyle of Cytosolic Bacteria. Nature Reviews Microbiology, 2009. 7: p. 333. 15. Webber, M.A. and L.J.V. Piddock, The Importance of Efflux Pumps in Bacterial Antibiotic Resistance. Journal of Antimicrobial Chemotherapy, 2003. 51(1): p. 9-11. 16. Lee, M.S. and Y.-J. Kim, Signaling Pathways Downstream of Pattern-Recognition Receptors and Their Cross Talk. Annual Review of Biochemistry, 2007. 76(1): p. 447-480. 17. Collier, M.A., et al., Delivery of Host Cell-Directed Therapeutics for Intracellular Pathogen Clearance. Expert Rev Anti Infect Ther, 2013. 11(11): p. 1225-35. 18. Koselny, K., et al., The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2016. 60(12): p. 7115-7127. 19. Collier, M.A., et al., Host-Mediated Leishmania donovani Treatment Using AR-12 Encapsulated in Acetalated Dextran Microparticles. Int J Pharm, 2016. 499(1-2): p. 186-194. 20. Chiu, H.-C., et al., Eradication of Intracellular Francisella tularensis in THP-1 Human Macrophages with a Novel Autophagy Inducing Agent. Journal of Biomedical Science, 2009. 16(1): p. 110-110. 21. Chiu, H.-C., et al., Eradication of Intracellular Salmonella enterica Serovar Typhimurium with a Small-Molecule, Host Cell-Directed Agent. Antimicrobial Agents and Chemotherapy, 2009. 53(12): p. 5236-5244. 22. Chiu, H.-C., et al., Pharmacological Exploitation of an Off-Target Antibacterial Effect of the Cyclooxygenase-2 Inhibitor Celecoxib against Francisella tularensis. Antimicrobial Agents and Chemotherapy, 2009. 53(7): p. 2998-3002. 23. Hoang, K.V., et al., Acetalated Dextran Encapsulated AR-12 as a Host-directed Therapy to Control Salmonella Infection. International journal of pharmaceutics, 2014. 477(0): p. 334-343. 24. Hoang, K.V., et al., Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge. Antimicrobial Agents and Chemotherapy, 2016. 60(4): p. 2052-2062. 25. Anderson, A.C., The Process of Structure-Based Drug Design. Chemistry & Biology, 2003. 10(9): p. 787-797. 26. Wickham, M.E., et al., Oral Infection of Mice with Salmonella entericaserovar Typhimurium Causes Meningitis and Infection of the Brain. BMC Infectious Diseases, 2007. 7(1): p. 65. 27. D. Owens, J., Food Microbiology: An Introduction, 2nd ed. by T.J. Montville and K.R. Mathews. ASM Press (2008), hard cover, US$89.95, ISBN: 978-1-55581-396. Vol. 21. 2010. 103-103. 28. Sood, S., et al., Re-emergence of Chloramphenicolsensitive Salmonella typhi. The Lancet, 1999. 353(9160): p. 1241-1242. 29. Chiu, C.-H., et al., The Emergence in Taiwan of Fluoroquinolone Resistance in Salmonella enterica Serotype Choleraesuis. New England Journal of Medicine, 2002. 346(6): p. 413-419. 30. Wu, J., et al., High-throughput Assay to Phenotype Salmonella enterica Typhimurium Association, Invasion, and Replication in Macrophages. Journal of Visualized Experiments : JoVE, 2014(90): p. 51759. 31. Mandell, G.L., Interaction of Intraleukocytic Bacteria and Antibiotics. Journal of Clinical Investigation, 1973. 52(7): p. 1673-1679. 32. Elsinghorst, E.A., Measurement of Invasion by Gentamicin Resistance, in Methods in Enzymology. 1994, Academic Press. p. 405-420. 33. Maw, J. and G.G. Meynell, The True Division and Death Rates of Salmonella typhimurium in the Mouse Spleen Determined with Superinfecting Phage P22. British Journal of Experimental Pathology, 1968. 49(6): p. 597-613. 34. Hapfelmeier, S. and W.-D. Hardt, A Mouse Model for S. typhimurium-Induced Enterocolitis. Trends in Microbiology, 2005. 13(10): p. 497-503. 35. Hormaeche, C.E., The in vivo Division and Death Rates of Salmonella typhimurium in the Spleens of Naturally Resistant and Susceptible Mice Measured by the Superinfecting Phage Technique of Meynell. Immunology, 1980. 41(4): p. 973-979. 36. L Birmingham, C., et al., Autophagy Controls Salmonella Infection in Response to Damage to the Salmonella-containing Vacuole. Vol. 281. 2006. 11374-83. 37. Zhu, J., et al., From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors. Cancer Research, 2004. 64(12): p. 4309. 38. Cockerill, F.R., et al., Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition. 2012. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71985 | - |
dc.description.abstract | 有些具有胞內寄生特性的病原菌,例如:Salmonella spp.會導致慢性的感染,這些病原菌會藉由入侵宿主細胞,來逃避外在抗生素的作用,並持續在細胞內存活而難以抗生素完全治癒以及容易造成抗藥性的產生。以宿主為標的的治療方法在許多研究中被提出來做為胞內細菌感染的治療。AR-12 (a.k.a. OSU-03012)原先是作為抗癌藥物,在我們過去的研究中發現AR-12合併胺基糖苷類抗生素可以顯著清除胞內細菌,使得AR-12有潛力成為一種治療胞內細菌感染的藥物,但是有鑑於AR-12對細胞的半數致死量(IC50)接近於一半抑菌濃度,所以決定進行AR-12結構優化。另外先前實驗室發現一個具有抑菌效力的抗精神疾病藥物-Loxapine,於合併胺基糖苷類抗生素可以顯著清除胞內細菌,且同時具高半數細胞致死量(IC50),然而在活體實驗並沒有延長小鼠存活率,因此我們期望藉由Loxapine結構修改所合成的衍生物找出具有潛力的藥物。在本研究中,我們取得了167個以AR-12為基礎合成的化合物以及5個Loxapine衍生物,針對胞內鼠傷寒沙門氏菌感染進行抑菌能力測試,同時對細胞進行毒性測試,找尋對抗胞內鼠傷寒沙門氏菌更有效且低毒性的藥物以及以Loxapine為代表探討其抑菌機制。
首先,我們進行了一系列結構類似的AR-12衍生物篩選,我們發現7個化合物具有低毒性且和AR-12相等的抑菌能力;另外7個化合物則展現優於AR-12的抑菌能力但是毒性與AR-12相等。我們進一步評估這14個化合物合併胺基糖苷類抗生素對治療胞內鼠傷寒沙門氏菌的效果。由細胞感染實驗結果發現,14個化合物中有4個沒有顯著的抑菌能力。接著在10個化合物中挑選出3個選擇性最高的化合物進行多重抗藥菌株的抑菌能力測試也展現出相同的效果。而在Loxapine細胞感染實驗與毒性測試結果發現,3個化合物展現優於Loxapine的抑菌能力,但是其細胞毒性亦伴隨著增加,因此並無高的選擇性。目前,AR-12衍生物與Loxapine衍生物還在繼續合成並測試中。 上述的實驗證明,以優化AR-12結構所合成的化合物可以展現優於AR-12的抑菌能力以及降低的毒性,候選化合物有潛力成為臨床上多重抗藥性之鼠傷寒沙門氏菌感染的新藥,並作為胺基糖苷類抗生素的佐劑共同使用。 | zh_TW |
dc.description.abstract | Some bacteria pathogens that can reside in host cells, for example: Salmonella spp. and will lead to chronic infection. These pathogens will invade host cells to evade external antibiotics’ attack and continue to survive in the cell, thus they are difficult to completely eradicated with antibiotics and often lead to drug resistance. Host-directed therapies have been proposed in many studies for the treatment of intracellular bacterial infections. AR-12 (a.k.a. OSU-03012), was originally used as an anti-cancer drug and have been showed in our previous studies that AR-12 combined with aminoglycoside antibiotics can significantly clear intracellular bacteria, making AR-12 as a potential drug for the treatment of intracellular bacterial infections. As the half-lethal dose (IC50) of AR-12 is close to half-effective concentration, we decided to conduct AR-12 structure optimization. In addition, we previously found that an antipsychotic drug - loxapine in combined with aminoglycoside antibiotics showed antimicrobial efficacy and significantly cleared intracellular bacteria with a high half-lethal dose (IC50), however, loxapine cannot prolong the survival of mice. Therefore, we hope to obtain potential drugs by synthesis of loxapine derivatives. In this study, we obtained 167 AR-12 derivatives and 5 loxapine derivatives. We tested the anti-bacterial activity against intracellular Salmonella Typhimurium of all compounds and simultaneously tested toxicity towards host cells to identify more effective and low toxicity drugs. At the same time, we used loxapine as the representative to explore its antibacterial mechanism.
First, we performed AR-12 derivative screening. We found that seven compounds have lower toxicity and equal antibacterial activity to AR-12. Another seven compounds showed better antibacterial activity but equal toxicity to AR-12. We further evaluated the efficacy of these 14 compounds in combination with aminoglycoside antibiotics for the treatment of intracellular S. Typhimurium. The results of the cell infection experiments showed that 4 of 14 compounds had no significant antibacterial activity. Subsequent test of the three compounds with highest selectivity for antibacterial activity against multidrug-resistant strains also demonstrated the same effect. In the cell infection test and toxicity test of loxapine, three compounds showed better antibacterial ability than loxapine, but with high toxicity, thus there was no high selectivity. At present, the synthesis and test of AR-12 derivatives and loxapine derivatives are ongoing. The above findings demonstrated that the antibacterial activity of AR-12 can be dissociated from its antiproliferative activity via structure optimization and that hit compounds are potential to be served as antibiotic adjuvants for MDR Salmonella Typhimurium infection. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:17:50Z (GMT). No. of bitstreams: 1 ntu-107-R05424024-1.pdf: 1115373 bytes, checksum: 01e61481012008ee64262d06b4ffae7b (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | Contents
致謝 i 中文摘要 ii Abstract iv Contents vi 1. Introduction 1 1.1 Intracellular Bacterial Infection and the Difficulties in Clinical Treatment 2 1.2 Host-directed Strategy Against Intracellular Bacteria 3 1.3 The Host-Directed Antibacterial Drug 4 1.4 Salmonella enterica serovar Typhimurum as the Model of Intracellular Bacteria 6 1.5 Specific aims 8 2. Materials and Methods 9 2.1 Bacterial strains and culture conditions 10 2.2 Cell line and culture condition 10 2.3 Drugs and reagents 11 2.4 High Content Screening 11 2.5 Cell Viability assay 12 2.6 Minimum Inhibitory Concentration Assay 13 2.7 Colony Forming Assay of Intracellular S. Typhimurium Growth Analysis 14 2.8 Statistical Analysis 15 3. Results 16 3.1 Identification of Compounds That Inhibit Intracellular Growth of S. Typhimurium in a Bulk Cell Infection Assay with High-Content System 17 3.2 Evaluation of The Anti-Intracellular S. Typhimurium Growth Activities of 14 Selected AR-12 Derivatives 18 3.3 Cytotoxicity of AR-12 Derivatives 18 3.4 Identification of Compounds That Inhibit Bacteria Growth in Axenic Medium 19 3.5 Anti-Intracellular Multidrug-Resistant S. Typhimurium Activities of RTI-2, RTI-8 and RTI-9 Combined Gentamicin 19 3.6 Antibacterial and Antiproliferative Effects of Loxapine Derivatives 20 4. Discussion 21 4.1 Whether the Combination of Hit Compounds and Gentamicin Is Effective to Increase the Survival Rate of S. Typhimurium-Infected Mice? 22 4.2 The Investigation of the Mechanism of Host-Directed Drugs 23 5. Reference 24 6. Tables 31 Table 1. Antiproliferative activity and bacteria inhibition effects of selected AR-12 derivatives towards RAW264.7 cells. 32 Table 2. Antiproliferative activity and bacteria inhibition effects of selected loxapine derivatives towards RAW264.7 cells. 33 7. Figures 34 Figure 1. Identification of compounds that inhibit intracellular growth of S. Typhimurium in a bulk cell infection assay with high-content screening. 35 Figure 2. The evaluation of the anti-intracellular S. Typhimurium growth activities of fourteen selected AR-12 derivatives. 39 Figure 3. Anti-intracellular multidrug-resistant S. Typhimurium activities of RTI-2, RTI-8 and RTI-9 combined gentamicin. 40 | |
dc.language.iso | zh-TW | |
dc.title | 評估以宿主為標的之抗胞內鼠傷寒沙門氏菌感染藥物 | zh_TW |
dc.title | Evaluation of Host-Directed Anti-Bacterial Agents Against Intracellular Salmonella Typhimurium | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭崇瑋,張永祺 | |
dc.subject.keyword | 沙門氏菌,胞內抑菌,合併藥物, | zh_TW |
dc.subject.keyword | Salmonella,anti-intracellular bacteria,drug combination, | en |
dc.relation.page | 40 | |
dc.identifier.doi | 10.6342/NTU201804056 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 1.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。